BACKGROUND: The association between black race and worse outcomes in operable breast cancer reported in previous studies has been attributed to a higher incidence of more aggressive triple-negative disease, disparities in care, and comorbidities. We evaluated associations between black race and outcomes, by tumor hormone receptor and HER2 expression, in patients who were treated with contemporary adjuvant therapy. METHODS: The effect of black race on disease-free and overall survival was evaluated using Cox proportional hazards models adjusted for multiple covariates in a clinical trial population that was treated with anthracycline- and taxane-containing chemotherapy. Categorical variables were compared using the Fisher exact test. All P values are two-sided. RESULTS: Of 4817 eligible patients, 405 (8.4%) were black. Compared with nonblack patients, black patients had a higher rate of triple-negative disease (31.9% vs 17.2%; P < .001) and a higher body mass index (median: 31.7 vs 27.4 kg/m(2); P < .001). Black race was statistically significantly associated with worse disease-free survival (5-year disease-free survival, black vs nonblack: 76.7% vs 84.5%; hazard ratio of recurrence or death = 1.58, 95% confidence interval = 1.19 to 2.10, P = .0015) and overall survival (5-year overall survival, black vs nonblack: 87.6% vs 91.9%; hazard ratio of death = 1.49, 95% confidence interval = 1.05 to 2.12, P = .025) in patients with hormone receptor-positive HER2-negative disease but not in patients with triple-negative or HER2-positive disease. In a model that included black race, hormone receptor-positive HER2-negative disease vs other subtypes, and their interaction, the interaction term was statistically significant for disease-free survival (P = .027) but not for overall survival (P = .086). CONCLUSION: Factors other than disparities in care or aggressive disease contribute to increased recurrence in black women with hormone receptor-positive breast cancer.
RCT Entities:
BACKGROUND: The association between black race and worse outcomes in operable breast cancer reported in previous studies has been attributed to a higher incidence of more aggressive triple-negative disease, disparities in care, and comorbidities. We evaluated associations between black race and outcomes, by tumorhormone receptor and HER2 expression, in patients who were treated with contemporary adjuvant therapy. METHODS: The effect of black race on disease-free and overall survival was evaluated using Cox proportional hazards models adjusted for multiple covariates in a clinical trial population that was treated with anthracycline- and taxane-containing chemotherapy. Categorical variables were compared using the Fisher exact test. All P values are two-sided. RESULTS: Of 4817 eligible patients, 405 (8.4%) were black. Compared with nonblack patients, black patients had a higher rate of triple-negative disease (31.9% vs 17.2%; P < .001) and a higher body mass index (median: 31.7 vs 27.4 kg/m(2); P < .001). Black race was statistically significantly associated with worse disease-free survival (5-year disease-free survival, black vs nonblack: 76.7% vs 84.5%; hazard ratio of recurrence or death = 1.58, 95% confidence interval = 1.19 to 2.10, P = .0015) and overall survival (5-year overall survival, black vs nonblack: 87.6% vs 91.9%; hazard ratio of death = 1.49, 95% confidence interval = 1.05 to 2.12, P = .025) in patients with hormone receptor-positive HER2-negative disease but not in patients with triple-negative or HER2-positive disease. In a model that included black race, hormone receptor-positive HER2-negative disease vs other subtypes, and their interaction, the interaction term was statistically significant for disease-free survival (P = .027) but not for overall survival (P = .086). CONCLUSION: Factors other than disparities in care or aggressive disease contribute to increased recurrence in black women with hormone receptor-positive breast cancer.
Authors: Dawn Hershman; Russell McBride; Judith S Jacobson; Lois Lamerato; Kevin Roberts; Victor R Grann; Alfred I Neugut Journal: J Clin Oncol Date: 2005-09-20 Impact factor: 44.544
Authors: C Martin Tammemagi; David Nerenz; Christine Neslund-Dudas; Carolyn Feldkamp; David Nathanson Journal: JAMA Date: 2005-10-12 Impact factor: 56.272
Authors: Lisa A Newman; James Mason; David Cote; Yael Vin; Kathryn Carolin; David Bouwman; Graham A Colditz Journal: Cancer Date: 2002-06-01 Impact factor: 6.860
Authors: Eric P Winer; Clifford Hudis; Harold J Burstein; Antonio C Wolff; Kathleen I Pritchard; James N Ingle; Rowan T Chlebowski; Richard Gelber; Stephan B Edge; Julie Gralow; Melody A Cobleigh; Eleftherios P Mamounas; Lori J Goldstein; Timothy J Whelan; Trevor J Powles; John Bryant; Cheryl Perkins; Judy Perotti; Susan Braun; Amy S Langer; George P Browman; Mark R Somerfield Journal: J Clin Oncol Date: 2004-11-15 Impact factor: 44.544
Authors: Deirdre A Hill; Marc Barry; Charles Wiggins; Andrea Nibbe; Melanie Royce; Eric Prossnitz; Lesley Lomo Journal: Breast Cancer Res Treat Date: 2017-08-19 Impact factor: 4.872
Authors: Sharon H Giordano; Sarah Temin; Jeffrey J Kirshner; Sarat Chandarlapaty; Jennie R Crews; Nancy E Davidson; Francisco J Esteva; Ana M Gonzalez-Angulo; Ian Krop; Jennifer Levinson; Nancy U Lin; Shanu Modi; Debra A Patt; Edith A Perez; Jane Perlmutter; Naren Ramakrishna; Eric P Winer Journal: J Clin Oncol Date: 2014-05-05 Impact factor: 44.544
Authors: Erica T Warner; Rulla M Tamimi; Melissa E Hughes; Rebecca A Ottesen; Yu-Ning Wong; Stephen B Edge; Richard L Theriault; Douglas W Blayney; Joyce C Niland; Eric P Winer; Jane C Weeks; Ann H Partridge Journal: J Clin Oncol Date: 2015-05-11 Impact factor: 44.544
Authors: Jung S Byun; Sandeep K Singhal; Samson Park; Dae Ik Yi; Tingfen Yan; Ambar Caban; Alana Jones; Partha Mukhopadhyay; Sara M Gil; Stephen M Hewitt; Lisa Newman; Melissa B Davis; Brittany D Jenkins; Jorge L Sepulveda; Adriana De Siervi; Anna María Nápoles; Nasreen A Vohra; Kevin Gardner Journal: Clin Cancer Res Date: 2020-01-07 Impact factor: 12.531
Authors: Yunan Han; Zhi-Feng Miao; Min Lian; Lindsay L Peterson; Graham A Colditz; Ying Liu Journal: Breast Cancer Res Treat Date: 2020-09-14 Impact factor: 4.872